Skip to main content
    J

    Jaguar Animal Health Inc (JAGX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.38
    -0.01 (-1.68%)

    Market Cap: $5.59M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Jaguar Animal Health Inc (JAGX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Jaguar Animal Health (JAGX) has a market cap of $5.59M and an enterprise value of $2.55M. Revenue grew 129.74% over the last 12 months from the 12 months before. It kept -122.26% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 54.30% below the market cap, as cash exceeds debt.

    Market Cap$5.59M
    Enterprise Value$2.55M
    Latest price (Nov 17, 2026)$0.38

    Key Dates

    The next earnings report is expected on Apr 5, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateApr 5, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 15.42% in the quarter ended Sep 30, 2026.

    Shares Outstanding684.37K
    Shares Change (QoQ)-15.42%

    Price Statistics

    The stock is down 99.90% over 52 weeks and trades 82.88% below its 50-day average.

    Beta (1Y)3.83
    52-Week Change-99.90%
    1-Month Change-86.53%
    3-Month Change-94.52%
    6-Month Change-98.49%
    5-Year Change-100.00%
    10-Year Change-100.00%
    Total Return (1Y)-99.90%
    Total Return (3Y CAGR)-98.58%
    Total Return (5Y CAGR)-97.46%
    Max Drawdown (1Y)-99.90%
    Max Drawdown (3Y)-100.00%
    Sharpe Ratio (1Y)-1.94
    Correlation with SPY (1Y)0.15
    50-Day Average$2.22
    200-Day Average$45.05
    52-Week Range$0.36 to $981.75
    RSI (14 Days)36.4
    Average Volume (20 Days)905.90K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.28x current liabilities, and total debt is 0.12x shareholder equity.

    Current Ratio1.28x
    Quick Ratio0.75x
    Debt / Equity0.12x
    Interest Coverage-6.04x

    Returns and Efficiency

    Return on invested capital is -98.36% over the last 12 months, against a 5-year average of -95.95%.

    Return on Equity (ROE)-162.90%
    Return on Assets (ROA)-101.82%
    Return on Invested Capital (ROIC)-98.36%
    Return on Capital Employed (ROCE)-144.32%
    ROA (5Y Average)-99.53%
    ROIC (5Y Average)-95.95%
    Asset Turnover0.66x
    Inventory Turnover0.71x
    Receivables Turnover56.82x
    Cash Conversion Cycle133 days

    Scores

    JAGX has an Altman Z-Score of -19.54, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-19.54
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $27.07M over the last 12 months.

    Revenue$27.07M
    Revenue Growth (YoY)+129.74%
    Gross Profit$22.06M
    Operating Income-$24.68M
    Pretax Income-$33.10M
    Net Income-$33.10M
    EBIT-$28.40M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 62.50% of the $32.51M in total assets.

    Cash and Equivalents$5.53M
    Total Debt$2.49M
    Net Cash$3.04M
    Net Cash Per Share$4.43
    Working Capital$3.56M
    Shareholder Equity$20.32M
    Book Value Per Share$29.69
    Tangible Book Value$5.70M
    Tangible Book Per Share$8.33
    Total Assets$32.51M
    Total Liabilities$13.89M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$6.92M
    FCF Per Share-$0.52
    Depreciation and Amortization$2.89M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -91.15%.

    Gross Margin81.47%
    Operating Margin-91.15%
    Pretax Margin-122.26%
    Net Margin-122.26%
    EBIT Margin-104.90%
    Gross Margin (5Y Average)71.78%

    Growth

    Revenue fell 1.26% a year over 3 years.

    Revenue Growth (3Y CAGR)-1.26%
    Revenue Growth (5Y CAGR)+4.17%

    Revenue and profit by year

    Dividends and Yields

    JAGX does not pay a dividend.

    Buyback Yield31.15%
    Shareholder Yield31.15%

    Stock Splits

    The last split was a 2-for-1 forward split on Oct 16, 2026.

    Last Split DateOct 16, 2026
    Split TypeForward split
    Split Ratio2:1

    Peer Position

    Against 3 similar companies, JAGX has the 2nd highest ROIC.

    ROIC-98.36% vs -247.19% median
    Revenue Growth (Trailing 4 Quarters, YoY)+129.74% vs -100.00% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About JAGX

    What is JAGX's market cap?

    Jaguar Animal Health has a market cap of $5.59M. Its enterprise value, which adds debt and subtracts cash, is $2.55M.

    How many shares of JAGX are outstanding?

    Jaguar Animal Health has 684.37K shares outstanding.

    Does JAGX pay a dividend?

    No. Jaguar Animal Health does not pay a dividend.

    How much debt does JAGX have?

    Jaguar Animal Health has $2.49M of total debt and $5.53M of cash and equivalents, a net cash position of $3.04M.